GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scandion Oncology AS (OSTO:SCOL) » Definitions » Loans Receivable

Scandion Oncology AS (OSTO:SCOL) Loans Receivable : kr0.00 Mil (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Scandion Oncology AS Loans Receivable?

Scandion Oncology AS's Loans Receivable for the quarter that ended in Dec. 2024 was kr0.00 Mil.


Scandion Oncology AS Loans Receivable Historical Data

The historical data trend for Scandion Oncology AS's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scandion Oncology AS Loans Receivable Chart

Scandion Oncology AS Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Loans Receivable
Get a 7-Day Free Trial - - - - -

Scandion Oncology AS Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Scandion Oncology AS Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Scandion Oncology AS Loans Receivable Related Terms

Thank you for viewing the detailed overview of Scandion Oncology AS's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Scandion Oncology AS Business Description

Traded in Other Exchanges
Address
Fruebjergvej 3, Symbion, Copenhagen, DNK, 2100
Scandion Oncology AS is a clinical-stage biotechnology company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options. Cancer Drug Resistance Company discovers and develops first-in-class medicines aimed at treating cancer that is resistant to current treatment options. The company's pipeline includes products like COROST for Colorectal Cancer, PANTAX for Pancreatic Cancer, 101 for other cancer indiction, 201 for Solid Tumors.

Scandion Oncology AS Headlines

No Headlines